Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Hair Restoration Dermatologists (US)(?)

Council Members in this Study Group: 227

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

What is a GLG Leader?
Michael Bain, MD
Plastic and Reconstructive Physician
Michael A Bain, MD

Michael Bain, MD, MS, is a Plastic and Reconstructive Physician in private practice based in Southern California. He has experience in all areas of plastic and reconstructive surgery including bariatric, breast, cosmetic, and reconstructive surgery. Dr. Bain’s interests are in the ever changing nature...


5 recent news post(s)
Brian Lester, MD
Dermatologist
Brian W Lester, MD

Brian Lester, MD, is a Dermatologist in private practice in Massachusetts. His interests include clinical dermatology, cosmetic dermatology, dermatopathology, and dermatologic pharmaceuticals. He has experience with clinical trials involving a variety of agents used in psoriasis (e.g. retinoids and...


Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology, Stanford UniversitySunil Dhawan, MD
Clinical Assistant Professor of Dermatology
Stanford University

Sunil Dhawan, MD, is a Clinical Assistant Professor of Dermatology at Stanford University. He has expertise in clinical dermatology including acne, rosacea, psoriasis, eczema, skin cancer, actinic keratosis, lasers and cosmetic dermatology, and managed care. Dr. Dhawan also runs the clinical trial division...


42 recent news post(s)
Michele Pauporte, MD, Dermatologist, Juva Skin and Laser CenterMichele Pauporte, MD
Dermatologist
Juva Skin and Laser Center

Michele Pauporte, MD, is a Dermatologist at Juva Skin and Laser Center, in New York City. Dr. Pauporte's areas of expertise include cosmetic procedures and the treatment of skin cancers (including Mohs micrographic surgery) and reconstructive surgery. She is also extremely experienced in the use of...


Robert Koppel
Owner
Koppel Dermatology

Robert Koppel, MD, is a Dermatologist in private practice in Metairie, Louisiana. He also serves as an Assistant Clinical Professor in the Department of Dermatology of Tulane University School of Medicine. Dr. Koppel is knowledgeable of all aspects of medical, surgical, and cosmetic dermatology, with...


Kenneth Edelson
Owner
Kenneth Edelson, MD

Kenneth Edelson, MD, FAACS, is a Dermatologist in private practice in New York. Dr. Edelson specializes in skin cancer as well as cosmetic dermatology, including lasers and IPL's for facial rejuvenation and skin tightening, vascular lesions, pigmentation, and cellulite. He also uses lasers for leg veins...


6 recent news post(s)

Related Study Groups

GLG NewsSMAnalyses by this Study Group's Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Long term use of Allergan's Botox does not decrease efficacy | 04-01-2008
Analysis of: Efficay of Bolinum toxin does not sag over time | www.medscape.com
Author: Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology, Stanford University

 This article is important in that it lays to rest a misconception that long term repeated use of Botox ( Allergan) leads to decreased efficacy. Efficacy was maintained, and no neutralizing antibodies were found to Botox. This will reassure most users of Botox, and patients as well.

Serious Skin Reactions with TNF antagonists | 04-01-2008
Analysis of: Serious Skin Reactions with TNF antagonists | www.medscape.com
Author: Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology, Stanford University

 This article is important in that it defined the incidence of serious skin reactions to the three common TNF antagonists- Enbrel, Humira, and Remicade. The incidence is relatively low in comparison to the numbers of patients treated. Any foreign protein has the potential for eliciting these reactions,...

AN2728 phase 2a results encouraging. | 03-31-2008
Analysis of: Anacor Pharmaceuticals Announces Positive Results from Phase 2A Clinical Trial of AN2728 in Psoriasis Patients | www.pipelinereview.com
Author: Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology, Stanford University

Anacor's recent release of the data from their phase 2a study of AN 2728  for psoriasis were encouraging.  Over 69% actively treated plaques of psoriasis improved versus only 6% of placebo treated plaques. The study was limited by the short duration- only 28 days versus up to 16...

Psoriasis associated with comorbidities- Is this to be expected? | 03-31-2008
Analysis of: Research Shows Patients With Psoriasis at Increased Risk for Developing Other Serious Medical Conditions | www.pharmalive.com
Author: Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology, Stanford University

 This article is important in that it is one of the first to confirm what is  a widely held belief among many dematologists who treat many patients with psoriasis. Specifically that these patients suffer a higher rate of cardiovascular diseases, depression, malignancy, etc. This makes perfect...

Ustekinumab shows promise | 03-19-2008
Analysis of: Novel Biologic Agent Proves Highly Effective in Severe Plaque Psoriasis | www.medscape.com
Author: Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology, Stanford University

Centocors new product- Ustekinumab /CNTO 1275 had impressive results in the recent PHOENIX trials and the application is under review at the FDA. The PASI score reductions are superior to the exiting agents such as Enbrel and Humira, and are comparable to those of the other Centocor product- Remicade...

View All GLG News by members of this Study Group

Most Common Company Types:

  • Office Based Private Practice or Clinic
  • Academic Medical Center/Hospital or Clinic

Most Common Job Types:

  • Physician - Attending Physician
  • Owner
  • Physician - Director
  • President
  • Director
  • Partner

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics